

J.P.Morgan

Q3 2025 Biopharma Licensing and Venture Report

October 2025

Fueled by

DEALFORMA 



Executive summary

While venture fundraising remains challenging, M&A offers a bright spot. IPO activity remains tepid in the U.S whereas Chinese dealmaking gathers steam

Biopharma continued to see fewer transactions allocated to more advanced programs in Q3 2025. Venture fundraising remained challenging across early and later rounds. Licensing transactions posted larger upfront payments and potential deal values as the largest biopharma dealmakers sought to partner with the most promising pipeline assets.

Two new biopharma IPOs listed on NASDAQ in Q3 2025. Biopharma M&A saw one deal at \$10 billion and two more above \$7 billion to put 2025 ahead of full-year 2024 M&A dollar volume.

Here are a few highlights from our Q3 2025 report:

- **Venture investment in therapeutics and discovery platforms:** \$5.8 billion invested in Q3 2025 in 86 rounds for biopharma companies, down from \$6.6 billion in Q3 2024.
- **Biopharma licensing partnerships:** \$61.5 billion in total announced deal value for biopharma licensing deals signed in Q3 2025, bringing the total to \$181.5 billion in 2025 YTD.
- **M&A:** 33 biopharma M&A transactions were announced in Q3 2025 totaling \$30.9 billion in upfront cash and equity.
- **IPOs:** \$1.1 billion across seven IPOs on NASDAQ completed through September 30, 2025, with two IPOs in Q3 2025 on U.S. exchanges.

J.P. Morgan is dedicated to your success. Our relationships, our capital, and our skilled team of bankers and specialists dedicated to the life sciences sector reflect our conviction in the pivotal contributions these clients are making to society, shareholders and employees alike.

Our bankers’ expertise ranges from advising companies at the earliest stage of formation to leading complex M&A and capital markets transactions. Regardless of the size or stage of your company, we are prepared and equipped to advise and support you in meeting your strategic and financial objectives.

Thank you for taking the time to read our report. We look forward to working with you.

Kathryn McDonough
Head of Life Sciences, Innovation Economy
Commercial Banking
J.P. Morgan

Parameters

Biopharma companies are defined as firms developing therapeutics and technology platforms engaged in drug discovery, clinical R&D and commercialization.


Therapy areas, development stages, modalities and deal structures are segmented per the DealForma database.

Financials are based on disclosed figures curated by DealForma. Multiple tranches of the same Series are counted as one together.


Data as of Sept. 30, 2025

Biopharma venture dollars increased QoQ but remain on pace for a YoY decline

QUARTERLY BIOPHARMA VENTURE INVESTMENT VS. ANNUAL VENTURE DEAL COUNT¹



10-YEAR U.S. TREASURY YIELD VS. BIOPHARMA VENTURE DEPLOYMENT (INDEXED)^{1,2}



Biopharma venture funding slowed to \$5.8 billion in Q3 2025, the smallest third-quarter total since 2022 and following a weak Q2. This decline continues the shift toward capital discipline in an elevated rate environment amid regulatory uncertainty throughout the year.


Venture activity remained cautious, with investment favoring more advanced therapeutic asset pipelines with near-term clinical and commercial potential.

Corporate venture capital funds remain active, participating in four of the 10 the largest deals of the quarter. Meanwhile, M&A activity has also increased, often with Big Pharma involved on one side of the transaction.


Notes: ¹Financials based on disclosed figures. Data through Sept. 30, 2025. ²Biopharma venture capital deployment is indexed to Q1 2020, where Q1 2020 = 100.

Licensing upfronts and venture rounds were selectively larger through Q3 2025

COUNT OF VENTURE INVESTMENT ROUNDS BY ROUND SIZE¹



COUNT OF R&D LICENSES BY DISCLOSED UPFRONT CASH AMOUNT¹




Fewer biopharma companies raised venture rounds through Q3 2025, but those that did were predominantly later-stage companies that attracted larger investments. There were 52 venture rounds of \$100 million or more. Notable Q3 2025 raises include: MapLight Therapeutics' \$372 million Series D, and ARTBIO's \$132 million Series B.

License deals continued to reward the most advanced and promising assets, though with fewer deals. There were 32 deals through Q3 2025 with \$100 million+ in upfront payments, compared to 33 in all of 2024. Notable deals with large-cap biopharma included Zealand Pharma's deal with Roche (\$1.4 billion at signing and \$250 million over two years), BioNTech's deal with Bristol Myers Squibb (\$1.5 billion up front and up to \$2 billion in non-contingent anniversary payments through 2028), and 3SBio's deal with Pfizer (\$1.3 billion up front and \$100 million in equity investment).

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Early-stage biopharma venture activity was lighter in Q3, widening the gap with later rounds

BIOPHARMA SEED AND SERIES A VENTURE ACTIVITY VS. SERIES B+ VENTURE ACTIVITY¹




Early-stage biopharma venture activity saw \$6 billion across 132 seed and Series A rounds through the end of Q3 2025, losing the momentum from earlier in the year and widening the gap with Series B+. Later rounds continued to lead biopharma venture activity with \$11.1 billion raised across 158 rounds. Seed and Series A deals continued to see more tranching structures as part of their financing agreements.

Large seed and Series A rounds in Q3 2025 were Ollin Biosciences’ seed round of \$100 million and Reunion Neuroscience’s Series A extension from 2024 to \$133 million.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Phase II pipelines continued to bring larger venture rounds

BIOPHARMA THERAPEUTICS AND PLATFORMS: MEDIAN VENTURE ROUND SIZE BY COMPANY STAGE AT FUNDING




Biopharma venture round median values continued to increase for Phase II companies, rising to \$63 million through Q3 2025 from \$50 million in 2024. This corresponds to the increase in Series B and later activity and an investor preference to fund assets with clearer development pathways, lower perceived risk and near-term approval catalysts.

Notable Phase II companies that completed financings in Q3 2025 include MapLight Therapeutics' \$373 million Series D and ARTBIO's \$132 million Series B.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Upfront cash accounts for a growing share of announced R&D licensing deal value

BIOPHARMA THERAPEUTICS AND PLATFORMS R&D LICENSING TOTALS AND UPFRONT CASH AS A PROPORTION OF DEAL VALUE¹




Biopharma licensing deals totaled \$181.5 billion in announced deal values through Q3 2025, with 8% of that value paid upfront—an increase from 7% in 2024 to match the share in 2021.

Select transactions include Monte Rosa Therapeutics (Novartis), Orna Therapeutics (Vertex Pharmaceuticals), and Superluminal Medicines (Eli Lilly).


Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

ADC biologics drove the largest licensing upfronts and venture round through Q3 2025

TOP BIOPHARMA MODALITIES: TOTAL SEED AND SERIES A VENTURE FUNDING¹



TOP BIOPHARMA MODALITIES: TOTAL LICENSING UPFRONT CASH AND EQUITY¹




Biologics continued to lead both early-stage venture investment and licensing activity. Large deals for antibody-drug conjugates contributed to the \$10 billion in total upfront cash and equity in licensing and the \$2.3 billion in seed and Series A investment.

Small molecules followed with \$1.6 billion in seed and Series A venture rounds and \$2.5 billion in total licensing upfront payments. Small molecules typically see lower development costs and well-understood regulatory pathways.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Big pharma made larger deal moves in Phase I as competition for key programs increased

IN-LICENSING BY BIG PHARMA: MEDIAN UPFRONT CASH & EQUITY AND NUMBER OF DEALS BY STAGE AT SIGNING¹




Large-cap biopharma companies (market cap of \$50 billion+) remained in active competition to secure the most promising therapeutic programs, and they did so at earlier clinical stages. Q3 2025 saw median upfront payments grow larger for Phase I programs, now at \$350 million across the eight deals signed this year, jumping from \$168 million in 2024.

Preclinical assets also attracted larger median upfront payments. The median upfront cash and equity value year to date is \$110 million, up from \$45 million in 2024.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025. Stage of lead asset in multi-asset deals.

Oncology deal terms: Big pharma paying more in upfronts and milestones for later-stage assets

IN-LICENSING BY BIG PHARMA: MEDIAN DEAL PAYMENTS AND NUMBER OF DEALS DISCLOSING VALUES BY STAGE AT SIGNING, ONCOLOGY ASSETS, 2024-2025 YTD¹




Oncology remains the most active therapeutic area for licensing and R&D partnerships with biopharma companies with a market cap of \$50 billion or more. From 2024 through Q3 2025, big pharma companies paid a median upfront of \$150 million for Phase II programs and over \$1 billion for Phase III assets.

Median milestone totals were larger as well, with over \$2 billion following deals signed in Phase II and more than \$7 billion in potential milestones for deals signed at Phase III, mainly in final approval and sales-based milestones.

Note: ¹Financials based on disclosed figures. Not all deals disclose all payment terms. Data through Sept. 30, 2025. Stage of lead asset in multi-asset deals.

Biologics and small molecules have remained the top modalities for R&D partnerships

R&D PARTNERSHIPS FOR TOP BIOPHARMA MODALITIES: TOTAL ANNOUNCED DEAL VALUE




Total announced licensing deal values for biologics reached \$23.3 billion in Q3 2025, adding to the \$32.4 billion announced in the second quarter, bringing the 2025 year-to-date total for biologics to \$97.5 billion. Antibody-drug conjugate programs led with headline deals, mainly in oncology.

Small molecule programs, which typically rank second, added \$25.2 billion in announced deal value during Q3 2025, the largest amount since Q1 2023.


Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Obesity and diabetes remain among the most active areas for recent dealmaking

R&D PARTNERSHIPS FOR BIOPHARMA THERAPEUTICS AND DRUG DISCOVERY:
OBESITY AND DIABETES



R&D PARTNERSHIPS FOR BIOPHARMA THERAPEUTICS AND DRUG DISCOVERY:
GLP-1, GLP-1R AND GIP TARGETED THERAPEUTICS




Population-level diseases such as obesity and diabetes continued to see R&D partnership activity reach record levels through Q3 2025 for both total announced deal values and upfront payments. Year to date, 18 R&D partnerships and licensing deals were signed for obesity and diabetes, totaling \$18.2 billion in announced potential deal value and \$2.7 billion in announced upfront cash and equity. The full year of 2024 saw 29 deals and \$8.4 billion in headline deal numbers.

Four deals included upfront payments of more than \$100 million, including Roche’s agreement with Zealand Pharma, which featured \$1.4 billion upfront plus \$250 million committed over two years. Four deals totaling \$8.6 billion in announced potential deal value were signed for GLP-1, GLP-1R and GIP targeted therapies through Q3 2025.


Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Global collaborations: Chinese biopharma continued to attract large-cap biopharma deal flow


GLOBAL LARGE-CAP BIOPHARMA IN-LICENSING FROM CHINESE BIOPHARMA: DEALS WITH AT LEAST \$50 MILLION PAID UP FRONT



SHARE OF GLOBAL BIG PHARMA DEALS WITH \$50M+ UPFRONT ORIGINATING FROM CHINA - DEAL COUNT



SHARE OF GLOBAL BIG PHARMA UPFRONTS OVER \$50M+ PAID TO CHINESE BIOPHARMA



The share of deals and dollars paid upfront by global large-cap biopharma companies (market cap of \$50 billion+) to Chinese domiciled biopharma has increased over the past two years.


As of the third quarter, 2025 saw \$3.5 billion in total announced upfront payments across 13 in-licensing deals, each with at least \$50 million paid upfront by global pharma to Chinese biopharma companies. This accounts for 38% of global pharma's large deal activity and 30% of their upfront payments directed to biopharma companies in China.

Meanwhile, the Hong Kong Stock Exchange has also seen increased activity YTD with seven biotech IPOs relative to three in all of 2024.


Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025. Deals among global large-cap biopharma and Chinese domiciled biopharma.

Biopharma M&A: An active year already topping last year's dollar volume


BIOPHARMA M&A ACTIVITY^{1,2}



MEDIAN M&A UPFRONT CASH AND EQUITY^{1,2}



COUNT OF M&A DEALS BY ACQUIRED COMPANY TYPE^{1,2}




Mid- and small-cap biopharma accounted for 57% of total biopharma acquisitions by deal count through Q3 2025, marking the second largest share behind Q2 2025. Median M&A value dipped in the third quarter, however, to \$303 million, down from \$516 million in the second quarter. Q3 2025 saw 33 announced M&A transactions for biopharma therapeutics and platform companies, totaling \$30.9 billion and placing 2025 ahead of full-year 2024 in dollar volume. Notable transactions this quarter include Merck acquiring Verona Pharma for \$10 billion, Genmab acquiring Merus for \$8.0 billion and Pfizer acquiring Metsera for \$7.3 billion.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025. ²Biopharma M&A with any buyer type, acquisition options, and reverse mergers.

2025 Biopharma IPO activity remains quiet

NASDAQ AND NYSE COMPLETED IPOs IN BIOPHARMA THERAPEUTICS AND PLATFORMS: TOTALS (\$B) AND COUNT^{1,2}



Only seven biopharma companies completed IPOs of \$15 million or more on U.S. exchanges through Q3 2025. These companies collectively raised \$1.1 billion. This marks the least active year since 2010, as the cautious environment persists. Q3 2025 IPOs included LB Pharmaceuticals (\$285 million) and Curanex Pharmaceuticals (\$17.3 million).

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025. ²includes only NASDAQ and NYSE IPOs over \$15 million. Excludes Kenvue, Inc. (Q2 2023, \$4.4B) and other OTC focused companies. IPOs by completion date.

Chase, J.P. Morgan, JPMorgan, JPMorgan Chase, and Story by J.P. Morgan are marketing names for certain businesses of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide (collectively, "JPMC", "We", "Our" or "Us", as the context may require). The information in this content (website, article, event invitation or other form) does not represent an offer or commitment to provide any product or service. The views, opinions, analyses, estimates and strategies, as the case may be ("views"), expressed in this content are those of the respective authors and speakers named in those pieces, and/or the JPMC departments that publish the content and may differ from those of JPMorgan Chase Commercial Banking and/or other JPMC employees and affiliates. These views are as of a certain date and often based on current market conditions, and are subject to change without notice. Any examples used are generic, hypothetical and for illustration purposes only. Any prices/quotes/statistics included have been obtained from sources deemed to be reliable, but we do not guarantee their accuracy or completeness. To the extent indices have been used in this content, please note that it is not possible to invest directly in an index. This is not a product of the Research Department of J.P. Morgan Securities LLC. This information in no way constitutes research and should not be treated as such. Any information related to cybersecurity provided is intended to help clients protect themselves from cyber fraud, not to provide a comprehensive list of all types of cyber fraud activities nor to identify all types of cybersecurity best practices.

Copying, re-publishing, or using this material or any of its contents for any other purpose is strictly prohibited without prior written consent from JPMorgan. In preparing this material, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information that was acquired from public sources. Any mentions of third-party trademarks, brand names, products and services are for referential purposes only and any mention thereof is not meant to imply any sponsorship, endorsement, or affiliation unless otherwise noted. Notwithstanding anything to the contrary, the statements in this material are not intended to be legally binding. Any products, services, terms or other matters described herein (other than in respect of confidentiality) are subject to, and superseded by, the terms of separate legally binding documentation and/or are subject to change without notice.

The information in this content is not advice on legal, tax, investment, accounting, regulatory, technology or other matters. You should always consult your own financial, legal, tax, accounting or similar advisors before making any financial or investment decisions, or entering into any agreement for JPMC products or services. In no event shall JPMC or any of its directors, officers, employees or agents be liable for any use of, for any decision made or action taken in reliance upon, or for any inaccuracies or errors in or omissions from, the information in this content. We are not acting as your or any client's agent, fiduciary or advisor, including, without limitation, as a Municipal Advisor under the Securities and Exchange Act of 1934. JPMC assumes no responsibility or liability whatsoever to you or any client with respect to such matters, and nothing herein shall amend or override the terms and conditions in the agreement(s) between JPMC and any client or other person.

The information in this content does not include all applicable terms or issues, and is not intended as an offer or solicitation for the purchase or sale of any product or service. Our products and services are subject to applicable laws and regulations, as well as our service terms and policies. Not all products and services are available in all geographic areas or to all customers. In addition, eligibility for particular products and services will be determined by JPMC, including satisfaction of applicable legal, tax, risk, credit and other due diligence, and JPMC's "know your customer", anti-money laundering, anti-terrorism and other policies and procedures. Credit is subject to approval. Rates and programs are subject to change. Certain restrictions apply.

Products and services may be provided by banking affiliates, securities affiliates or other JPMC affiliates or entities. In particular, securities brokerage services other than those that can be provided by banking affiliates will be provided by appropriate registered broker/dealer affiliates, including J.P. Morgan Securities LLC and J.P. Morgan Institutional Investments Inc. Any securities provided or otherwise administered by such brokerage services are not deposits or other obligations of, and are not guaranteed by, any banking affiliate and are not insured by the Federal Deposit Insurance Corporation. Certain financial products and services are required by law to be provided only by licensed representatives and affiliates. Inquiries regarding such products and services will be referred to a licensed representative or a licensed affiliate. The information in this content is not an offer to sell, or solicit an offer to purchase, any securities by anyone in any jurisdiction in which such offer or solicitation is not authorized, or in which JPMC or the person making such an offer is not qualified to do so, or to anyone to whom it is unlawful to make such an offer or solicitation, or to anyone in any jurisdiction outside of the United States. Nothing in this content constitutes any commitment by JPMC to underwrite, subscribe for or place any securities, or to extend or arrange credit, or to provide any other product or service. JPMC contact persons may be employees or officers of any JPMC subsidiary or affiliate.

Any information requested on this invitation, page or other relevant registration form will be processed for the purposes of preparation and administration of this event. Providing the requested information will also assist us in ensuring that the event is properly tailored to meet the requirements of the attendees. By providing the information requested, you are consenting to your data being processed by employees and agents of JPMC as well as potential co-organizers for these purposes. You expressly consent to our use of your information in the manner described herein and in our privacy policy (www.jpmorgan.com/privacy).

Please note that any JPMC-hosted event or webinar that you register to attend may be recorded, and videos, photographs and other recordings may be taken, where you may be captured participating in the event. By providing the information requested on the registration form, you consent to the publication of such photographs, videos, recordings and/or likenesses (whether edited, adapted, modified or copied), and their use by us and those that we authorize, without prior notice or compensation, in any way which we may see fit now or in the future, including but not limited to, marketing and advertising. Further, you release JPMC and its employees and agents from all claims of every kind on account of such use. You also acknowledge and agree that the replay links, if any, will be shared with JPMC clients and prospects who were invited but did not register/attend, and also potentially to other third parties if the topics are relevant to them. If you do not agree with any statements in this paragraph, please make a member of our staff aware on the day of the event.

The statements made in this content or during this event, or provided in materials as part of this event, are proprietary to JPMC and are not intended to be legally binding. Any products and services described during these events are offered by JPMC subject to applicable laws and regulations and service terms.

We will provide reasonable accessibility accommodations brought to our attention.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: <https://www.jpmorgan.com/IBOR>.

© 2025 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A., organized under the laws of the U.S.A. with limited liability. Deposits held in non-U.S. branches, are not FDIC insured.